[Pharmacogenomics in gynecology. Replies to the Zurich Discussion Panel].
Huber
J C
JC
Universitätsfrauenklinikum, Vienna, Austria. johnannes_huber@akh-wien.ac.at
Schneeberger
C
C
Noe
Marion
M
Tempfer
C
C
D000328:Adult; D000544:Alzheimer Disease / Q000235:genetics; D001141:Aromatase / Q000235:genetics; D001161:Arteriosclerosis / Q000235:genetics; D001943:Breast Neoplasms / Q000201:enzymology / Q000235:genetics*; D019363:Cytochrome P-450 CYP1A1 / Q000235:genetics; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D005260:Female; D005819:Genetic Markers; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D005838:Genotype; D006176:Gynecology; D020249:Hormone Replacement Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009154:Mutation; D010597:Pharmacogenetics; D010641:Phenotype; D011110:Polymorphism, Genetic; D011516:Prothrombin / Q000235:genetics; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013923:Thromboembolism / Q000235:genetics
D005819:Genetic Markers; D011516:Prothrombin; D003577:Cytochrome P-450 Enzyme System; D001141:Aromatase; D019363:Cytochrome P-450 CYP1A1